Science News

Antibody-based vaccine for HIV

Fri, 2nd Dec 2011

Chris Smith

Listen Now    Download as mp3 from the show Underwater Archaeology and Underwater Welding

A modified virus encoding an anti-AIDS antibody can protect animalsHIV-1 particles assembling at the surface of an infected macrophage. from HIV infection.

An estimated 7000 new cases of HIV occur each day, the majority of them in developing countries where access to heathcare and antiretroviral drugs is limited. For this reason, a vaccine is urgently needed to control the spread of the infection.

Previous vaccine strategies have performed poorly, barely making a dent in infection rates, and so far the only intervention with proven longterm efficacy has been circumcision, which reduces a man's risk of acquiring the disease by 60-80%.

But a paper published this week in Nature by Caltech scientist David Baltimore and his colleagues might hint at a new way to combat the problem. They've used a self-complementary adeno-associated virus 8 (scAAV-8) as a vector, to ferry into experimental animals the DNA code for an antibody called b-12, which has HIV-neutralising properties.

This antibody, discovered some years ago, is special because it has the capacity to disable many different strains of HIV and can prevent infection becoming established in the first place.

The Caltech team injected 100 billion particles of the scAAV-8 vector into the leg muscles of experimental mice. These animals had also been modified to carry in their bloodstreams the human CD4 white cells targeted by HIV.

Within a week, high levels of the human b-12 antibody were detectable in the blood of the mice and expression was sustained for at least one year, which was the duration of the experiment.

The researchers then challenged the animals with an injection of HIV sufficiently large to infect the vast majority of unvaccinated mice and tracked the numbers of CD4 cells circulating in the bloodstream.

Compared with control mice, in which the CD4 count dropped nearly to zero, the b-12 antibody-producing animals showed complete protection against the infection.

The result is stunning, but not without a few residual wrinkles that need ironing out. This is a study in mice and so the concept would need to be proven in humans. Also, the long-term tolerability and safety of sc-AAV vectors and the effect of sustained high-level expression of the b-12 antibody are unknown, and it's unclear how much of the viral vector would be required to protect larger species including humans.

However, according to the team, who dub their technique "VIP" - vectored immunoprophylaxis - "given the level of protection that VIP has demonstrated in vivo, we believe that highly effective prophylaxis through expression of existing monoclonal antibodies against HIV in humans is achievable."

References

Multimedia

Subscribe Free

Related Content

Comments

Make a comment

Very interesting application of gene therapy. 

Was the experimental group also tested with an HIV PCR?  Or other HIV antibodies?

Certainly there will need to be tests for long-term efficacy with multiple exposures to the virus.

If a vaccine can be developed, perhaps the disease can be eliminated in the next few decades.

I wonder if a similar method could be developed against Plasmodium Falciparum.  In some areas, the two vaccines could be delivered together.
CliffordK, Sat, 3rd Dec 2011

AIDs vaccines of many types has been actively pursued for a good while with little to any success. Some attribute this to lack of fcus - moneys are spread unproductively - alot of money but heavily diluted among concepts and substantial bureaucracy.
Phil1907, Sun, 4th Dec 2011

Indeed very interesting.
I guess this sc-AAV 8 vector could be developed as a platform for vaccines against a wide range of diseases.

I foresee a great future for human-virus interaction, going from diseases to treatments Nizzle, Mon, 5th Dec 2011



I disagree.
Perhaps more funding would help, but HIV/AIDS is one tough disease to fight.  And, over the last few decades there have been tremendous strides forward in the treatment.

There actually is a viable vaccine.  However, the vaccine is only 31% effective..  Very statistically significant.  Yet, not the same efficacy as what people get used to with other vaccines.  Imagine the benefit in countries where 1/4 of the population is infected with HIV, if one could reduce the new infection rate by 1/3.

Anyway, putting all of one's eggs in one basket is not wise.

Creating viruses that make our own antibodies is a very novel approach to vaccination, and might never have been tried if all the funding was held by a lab that was trying a more traditional approach to vaccine development.

If we have one chance to wipe out this killer disease.  Perhaps we should wait to distribute any vaccine until we can make a multi-vaccine cocktail, just like the multi-drug regimens that are being used to treat the disease.  And, then have required booster-shots for high risk individuals. CliffordK, Mon, 5th Dec 2011

See the whole discussion | Make a comment